US Patent No: 7,749,542

Number of patents in Portfolio can not be more than 2000

Opioid agonist/antagonist combinations

ALSO PUBLISHED AS: 20080292694
1 Status Updates

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
PURDUE PHARMA L.P.STAMFORD, CT314

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Colucci, Robert D Newtown, US 19 906
Kaiko, Robert F Weston, US 43 1619

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (5)
5,376,662 Method of attenuating nerve injury induced pain 56 1993
2004/0092,542 Tamper-resistant oral opioid agonist formulations 38 2003
2005/0095,291 Tamper-resistant oral opioid agonist formulations 49 2003
2005/0181,046 Tamper-resistant oral opioid agonist formulations 36 2003
2006/0039,970 Tamper-resistant oral opioid agonist formulations 26 2003
 
NOVA PHARMACEUTICAL CORPORATION (2)
4,760,069 Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists 70 1985
4,889,860 Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists 73 1987
 
The Lynx Project Limited (1)
6,310,072 Production of analgesic synergy by co-administration of sub-analgesic doses of a MU opioid agonist and a kappa-2 opioid agonist 53 1997
 
VIRGINIA COMMONWEALTH UNIVERSITY (4)
5,352,683 Method for the treatment of chronic pain 92 1993
5,321,012 Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance 139 1993
5,502,058 Method for the treatment of pain 122 1994
5,556,838 Inhibiting the development of tolerance to and/or dependence on an addictive substance 125 1994
 
NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (1)
5,225,440 Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase 61 1991
 
Eli Lilly and Company (1)
5,998,434 Composition for treating pain 49 1998
 
SLOAN-KETTERING INSTITUTE FOR CANCER RES (1)
4,803,208 Opiate agonists and antagonists 58 1985
 
ICN HUNGARY RT. (1)
5,317,022 Pharmaceutical composition and use 61 1992
 
G.D. SEARLE & CO. (1)
5,616,601 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation 127 1995
 
SCULLY SCOTT MURPHY & PRESSER, PC (1)
5,426,112 Growth regulation and related applications of opioid antagonists 98 1993
 
BAKER NORTON PHARMACEUTICALS, INC. (1)
4,873,076 Method of safely providing anesthesia or conscious sedation 67 1989
 
Omeros Corporation (2)
5,858,017 Urologic irrigation solution and method for inhibition of pain, inflammation and spasm 110 1996
5,860,950 Arthroscopic irrigation solution and method for inhibition of pain and inflammation 96 1996
 
COLMAN PRODUCTS LIMITED (1)
4,935,428 Treating opiate dependence 78 1988
 
PEPTECH LIMITED (1)
5,534,492 Muramyl peptide for the treatment of toxicity 51 1995
 
The Rockefeller University (3)
4,987,136 Method for controlling gastrointestinal dysmotility 115 1986
4,769,372 Method of treating patients suffering from chronic pain or chronic cough 101 1986
4,785,000 Method of treating patients suffering from chronic pain or chronic cough 72 1987
 
ADIR ET COMPAGNIE (1)
5,130,311 Oxazolopyridine compounds, compositions and use 58 1991
 
Schaap; Robert J. (2)
5,316,759 Agonist-antagonist combination to reduce the use of nicotine and other drugs 74 1992
5,574,052 Agonist-antagonist combination to reduce the use of nicotine and other drugs 125 1994
 
E. I. DU PONT DE NEMOURS AND COMPANY (2)
4,451,470 Analgesic, antagonist, and/or anorectic 14-fluoromorphinans 65 1982
5,593,994 Prostaglandin synthase inhibitors 75 1994
 
BRISTOL-MYERS SQUIBB COMPANY (1)
4,457,933 Prevention of analgesic abuse 116 1981
 
DynaGen, Inc. (1)
5,486,362 Controlled, sustained release delivery system for treating drug dependency 104 1993
 
MERCK SHARP & DOHME LTD. (1)
5,880,132 Tachykinin antagonist and an opioid analgesic effective at treating pain or nociception 61 1997
 
WARNER-LAMBERT COMPANY (1)
5,149,538 Misuse-resistive transdermal opioid dosage form 159 1991
 
UNIVERSITY OF CHICAGO, THE (4)
4,719,215 Quaternary derivatives of noroxymorphone which relieve nausea and emesis 91 1986
4,861,781 Quaternary derivatives of noroxymorphone which relieve nausea and emesis 86 1987
5,102,887 Method for reducing emesis and nausea induced by the administration of an emesis causing agent 85 1990
5,972,954 Use of methylnaltrexone and related compounds 102 1997
 
United Biomedical, Inc. (1)
5,633,259 Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction 54 1995
 
OREGON, UNIVERSITY OF (1)
5,514,680 Glycine receptor antagonists and the use thereof 76 1993
 
MERCK FROSST COMPANY (1)
5,474,995 Phenyl heterocycles as cox-2 inhibitors 165 1994
 
CONTRAL CLINICS OY (3)
4,882,335 Method for treating alcohol-drinking response 79 1988
5,096,715 Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist 62 1989
5,086,058 Method for treating alcoholism with nalmefene 76 1990
 
ALZA CORPORATION (4)
4,573,995 Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine 143 1984
5,236,714 Abusable substance dosage form having reduced abuse potential 106 1988
5,460,826 Morphine therapy 105 1994
5,866,164 Composition and dosage form comprising opioid antagonist 141 1997
 
YOUNG, JACQUELINE, MS. (1)
5,356,900 Method of treating chronic herpes virus infections using an opiate receptor antagonist 58 1993
 
SIMON, DAVID L. (1)
6,103,258 Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics 48 1998
 
MERCK FROSST CANADA LTD. (10)
5,409,944 Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase 80 1993
5,604,260 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 95 1993
5,436,265 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents 96 1993
5,521,213 Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 105 1994
5,552,422 Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents 113 1995
5,536,752 Phenyl heterocycles as COX-2 inhibitors 91 1995
5,550,142 Phenyl heterocycles as cox-2 inhibitors 96 1995
5,510,368 N-benzyl-3-indoleacetic acids as antiinflammatory drugs 98 1995
5,604,253 N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors 84 1995
5,639,780 N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors 83 1995
 
EURO-CELTIQUE S.A. (36)
4,366,310 Controlled release compositions 58 1980
4,443,428 Extended action controlled release compositions 101 1982
4,940,587 Oral pharmaceutical composition through mucosa 110 1986
4,844,907 Pharmaceutical composition comprising analgesic and anti-inflammatory agent 129 1986
4,834,965 Controlled release pharmaceutical composition 88 1987
4,867,985 Spheroids 87 1988
5,071,646 Pharmaceutical ion exchange resin composition 118 1989
5,091,189 Controlled release dosage forms having a defined water content 45 1991
5,215,758 Controlled release matrix suppository for pharmaceuticals 90 1991
5,324,351 Aqueous dispersions of zein and preparation thereof 102 1992
5,356,467 Controlled release coatings derived from aqueous dispersions of zein 163 1993
5,500,227 Immediate release tablet cores of insoluble drugs having sustained-release coating 153 1993
5,622,722 Spheroid formulation 44 1994
5,508,043 Controlled release matrix for pharmaceuticals 52 1995
5,670,172 Pharmaceutical spheroid formulation 76 1995
6,024,982 Immediate release tablet cores of insoluble drugs having sustained-release coating 103 1995
5,811,126 Controlled release matrix for pharmaceuticals 83 1995
5,763,452 Pharmaceutical compositions and usages 43 1996
5,849,240 Method of preparing sustained release pharmaceutical compositions 123 1996
5,891,471 Pharmaceutical multiparticulates 108 1996
5,601,845 Pharmaceutical spheroid formulation 90 1996
5,843,480 Controlled release diamorphine formulation 86 1996
5,879,705 Sustained release compositions of morphine and a method of preparing pharmaceutical compositions 118 1997
5,908,848 Synergistic composition of codine and ibuprofen to treat arthritis 45 1997
5,942,241 Formulations and methods for providing prolonged local anesthesia 130 1997
6,068,855 Pharmaceutical composition containing a fusible carrier and method for producing the same 70 1997
5,965,163 Substained release compositions and a method of preparing pharmaceutical compositions 117 1997
6,077,532 Pharmaceutical ion exchange resin composition 51 1998
6,306,438 Stabilized sustained release tramadol formulations 70 1998
6,399,096 Pharmaceutical formulation 76 1998
6,143,328 Sustained release compositions and a method of preparing pharmaceutical compositions 58 1999
6,162,467 Sustained release compositions and a method of preparing pharmaceutical compositions 90 1999
6,210,714 Immediate release tablet cores of acetaminophen having sustained-release coating 74 2000
6,387,404 Immediate release tablet cores of insoluble drugs having sustained-release coating 84 2001
6,716,449 Controlled-release compositions containing opioid agonist and antagonist 81 2001
6,627,635 Method of preventing abuse of opioid dosage forms 95 2001
 
Purdue Pharma L.P. (39)
4,828,836 Controlled release pharmaceutical composition 188 1987
4,834,985 Controlled release pharmaceutical composition 203 1987
4,990,341 Controlled release hydromorphone composition 135 1989
5,266,331 Controlled release oxycodone compositions 173 1991
5,273,760 Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer 203 1991
5,286,493 Stabilized controlled release formulations having acrylic polymer coating 199 1992
5,549,912 Controlled release oxycodone compositions 167 1993
5,472,712 Controlled-release formulations coated with aqueous dispersions of ethylcellulose 183 1993
5,478,577 Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level 179 1993
5,411,745 Powder-layered morphine sulfate formulations 112 1994
5,965,161 Extruded multi-particulates 130 1994
5,639,476 Controlled release formulations coated with aqueous dispersions of acrylic polymers 399 1995
5,508,042 Controlled release oxycodone compositions 178 1995
5,968,551 Orally administrable opioid formulations having extended duration of effect 182 1995
5,958,459 Opioid formulations having extended controlled released 111 1995
5,656,295 Controlled release oxycodone compositions 152 1996
5,681,585 Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer 104 1996
5,672,360 Method of treating pain by administering 24 hour oral opioid formulations 177 1996
6,143,322 Method of treating humans with opioid formulations having extended controlled release 122 1997
5,958,452 Extruded orally administrable opioid formulations 162 1997
5,968,547 Method of providing sustained analgesia with buprenorphine 87 1997
6,077,533 Powder-layered oral dosage forms 65 1998
6,228,863 Method of preventing abuse of opioid dosage forms 147 1998
* 6,277,384 Opioid agonist/antagonist combinations 104 1998
6,103,261 Opioid formulations having extended controlled release 115 1999
6,335,033 Melt-extrusion multiparticulates 85 1999
6,261,599 Melt-extruded orally administrable opioid formulations 132 1999
6,294,195 Orally administrable opioid formulations having extended duration of effect 118 1999
6,375,957 Opioid agonist/opioid antagonist/acetaminophen combinations 149 2000
6,696,088 Tamper-resistant oral opioid agonist formulations 114 2001
* 6,475,494 Opioid agonist/antagonist combinations 82 2001
2003/0069,263 Pharmaceutical combinations of oxycodone and naloxone 54 2002
2003/0073,714 Opioid agonist formulations with releasable and sequestered antagonist 53 2002
* 6,696,066 Opioid agonist/antagonist combinations 115 2002
2003/0229,111 Naltrexone hydrochloride compositions 20 2003
2004/0186,121 Tamper-resistant oral opioid agonist formulations 44 2003
* 7,172,767 Opioid agonist / antagonist combinations 64 2003
2006/0182,801 Sequestered antagonist formulations 41 2006
* 7,419,686 Opioid agonist/antagonist combinations 39 2006
 
EUROCELTIQUE S.A., 122, BOULEVARD DE LA PETRUSSE, LUXEMBOURG (2)
4,844,909 Controlled release hydromorphone composition 128 1987
4,844,910 Spheroids 54 1987
 
McGinnis; Carolyn (1)
4,608,376 Opiate agonists and antagonists 54 1982
 
Aminotek Sciences, Inc. (1)
5,256,669 Methods and compositions for treating acute or chronic pain and drug addiction 62 1992
 
UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (1)
4,464,378 Method of administering narcotic antagonists and analgesics and novel dosage forms containing same 165 1981
 
The United States of America as represented by the Secretary of the Army (1)
5,834,477 Opiate analgesic formulation with improved safety 45 1994
 
GENERAL ELECTRIC COMPANY (1)
5,226,331 Apparatus and method for measuring the particle number rate and the velocity distribution of a sprayed stream 43 1991
 
RUTGERS, STATE UNIVERSITY OF NEW JERSEY, THE, OLD QUEEN BUILDING, SOMERSET AND GEORGE STREETS, NEW BRUNSWICK, NJ 08903 (1)
4,806,341 Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration 128 1986
 
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (12)
5,472,943 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists 98 1993
5,585,348 Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia 78 1993
* 5,512,578 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists 100 1994
5,624,932 Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction 52 1995
* 5,580,876 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 84 1995
5,767,125 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 85 1996
6,096,756 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 87 1998
6,194,382 Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists 52 1999
2001/0006,967 METHOD OF SIMULTANEOUSLY ENHANCING ANALGESIC POTENCY AND ATTENUATING ADVERSE SIDE EFFECTS CAUSED BY TRAMADOL AND OTHER BIMODALLY-ACTING OPIOID AGONISTS 27 1999
6,362,194 Method and simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 44 2000
6,395,705 Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists 49 2001
6,765,010 Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects 42 2002
 
RECKITT BENCKISER HEALTHCARE (UK) LIMITED (2)
4,582,835 Analgesic compositions 117 1984
4,661,492 Analgesic compositions 82 1985
 
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (1)
4,806,543 Method and compositions for reducing neurotoxic injury 80 1986
 
REGENTS OF THE UNIVERSITY OF MINNESOTA (6)
4,401,672 Non-addictive narcotic antitussive preparation 64 1981
4,730,048 Gut-selective opiates 87 1985
5,352,680 Delta opioid receptor antagonists to block opioid agonist tolerance and dependence 106 1992
5,457,208 Kappa opioid receptor antagonists 76 1993
5,578,725 Delta opioid receptor antagonists 58 1995
5,780,479 Use of opioid antagonists to treat impulse-control disorders 55 1997
 
MCLEAN HOSPITAL CORPORATION, THE (1)
5,075,341 Treatment for cocaine abuse 127 1989
 
Ortho-McNeil Pharmaceutical, Inc. (1)
5,336,691 Composition comprising a tramadol material and acetaminophen and its use 80 1992
 
NAPP PHARMACEUTICAL GROUP LIMITED (3)
5,591,452 Controlled release formulation 89 1994
6,326,027 Controlled release formulation 80 1995
6,254,887 Controlled release tramadol 80 1996
 
ENCINAL PHARMACEUTICAL INVESTMENTS, LLC (1)
5,869,097 Method of therapy comprising an osmotic caplet 69 1992
 
PURDUE PHARMA COMPANY, THE (2)
4,861,598 Controlled release bases for pharmaceuticals 168 1986
4,970,075 Controlled release bases for pharmaceuticals 139 1989
 
DUPONT MERCK PHARMACEUTICAL COMPANY, THE (1)
4,722,928 N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans having improved oral bioavailability, pharmaceutical compositions, and processes 27 1985
 
PUREUE PHARMA L.P. (1)
4,834,984 Controlled release dihydrocodeine composition 122 1987
 
LIFESHIELD SCIENCES LLC (1)
2004/0158,312 Braided endoluminal device having tapered filaments 10 2003
 
BASF AKTIENGESELLSCHAFT (2)
4,806,558 Diarylacetylenes and their use in treating acne 56 1985
4,957,681 Preparation of pharmaceutical mixtures 103 1989
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
Purdue Pharma L.P. (13)
8,518,925 Opioids for the treatment of the chronic obstructive pulmonary disease (COPD) 2 2005
9,101,625 Buprenorphine-wafer for drug substitution therapy 0 2007
8,987,290 Use of opioid formulations in needle-less drug delivery devices 0 2007
* 8,105,631 Opioid agonist/antagonist combinations 18 2010
8,673,355 Opioid agonist/antagonist combinations 2 2011
8,846,090 Matrix for sustained, invariant and independent release of active compounds 2 2012
8,822,487 Opioid agonist/opioid antagonist/acetaminophen combinations 2 2012
8,846,091 Matrix for sustained, invariant and independent release of active compounds 2 2013
9,084,729 Abuse-resistant controlled-release opioid dosage form 0 2013
8,969,369 Abuse-resistant controlled-release opioid dosage form 0 2013
9,056,051 Abuse-resistant controlled-release opioid dosage form 0 2014
8,936,808 Opioid agonist/opioid antagonist/acetaminophen combinations 1 2014
8,932,630 Opioid agonist/antagonist combinations 1 2014
 
QRXPHARMA LTD (1)
* 8,933,092 Methods and compositions comprising sequential administration opioid receptor agonists 0 2012
 
EGALET LTD. (5)
8,877,241 Morphine controlled release system 1 2004
9,005,660 Immediate release composition resistant to abuse by intake of alcohol 0 2010
9,023,394 Formulations and methods for the controlled release of active drug substances 0 2013
8,808,745 Morphine polymer release system 3 2013
9,044,402 Abuse-deterrent pharmaceutical compositions for controlled release 0 2014
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 6, 2018
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 6, 2022
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00